losartan has been researched along with Cardiotoxicity in 2 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Cardiotoxicity: Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib, a tyrosine kinase inhibitor that is used in the treatment of hepatocellular and renal cell carcinoma, was reported to induce cardiotoxicity." | 7.96 | The protective effect of losartan against sorafenib induced cardiotoxicity: Ex-vivo isolated heart and metabolites profiling studies in rat. ( Abdelgalil, AA; Ahamad, SR; Al-Jenoobi, FI; Mohamed, OY, 2020) |
| "Sorafenib, a tyrosine kinase inhibitor that is used in the treatment of hepatocellular and renal cell carcinoma, was reported to induce cardiotoxicity." | 3.96 | The protective effect of losartan against sorafenib induced cardiotoxicity: Ex-vivo isolated heart and metabolites profiling studies in rat. ( Abdelgalil, AA; Ahamad, SR; Al-Jenoobi, FI; Mohamed, OY, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Freiwan, M | 1 |
| Kovács, MG | 1 |
| Kovács, ZZA | 1 |
| Szűcs, G | 1 |
| Dinh, H | 1 |
| Losonczi, R | 1 |
| Siska, A | 1 |
| Kriston, A | 1 |
| Kovács, F | 1 |
| Horváth, P | 1 |
| Földesi, I | 1 |
| Cserni, G | 1 |
| Dux, L | 1 |
| Csont, T | 1 |
| Sárközy, M | 1 |
| Abdelgalil, AA | 1 |
| Mohamed, OY | 1 |
| Ahamad, SR | 1 |
| Al-Jenoobi, FI | 1 |
2 other studies available for losartan and Cardiotoxicity
| Article | Year |
|---|---|
Investigation of the Antiremodeling Effects of Losartan, Mirabegron and Their Combination on the Development of Doxorubicin-Induced Chronic Cardiotoxicity in a Rat Model.
Topics: Acetanilides; Animals; Cardiomyopathies; Cardiotoxicity; Doxorubicin; Losartan; Male; Rats; Rats, Wi | 2022 |
The protective effect of losartan against sorafenib induced cardiotoxicity: Ex-vivo isolated heart and metabolites profiling studies in rat.
Topics: Animals; Antineoplastic Agents; Cardiotonic Agents; Cardiotoxicity; Heart; Heart Rate; Losartan; Mal | 2020 |